Making every breath matter

Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo.

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.

Researchers are advising against the interruption of treatment with Gleevec among patients with advanced gastrointestinal stromal tumors.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

Patients with soft tissue sarcomas showed improved functional results, quality of life and fewer side effects when treated with RT-therapy.

An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved progression and survival.